PCA
CHRS icon

Pallas Capital Advisors’s Coherus Oncology CHRS Stock Holding History

Pallas Capital Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.5K Buy
+11,545
New +$20.5K ﹤0.01% 853
2025
Q3 		– Sell
-13,696
Closed -$10K – 891
2025
Q2 		$10K Buy
13,696
+938
+7% +$810 ﹤0.01% 855
2025
Q1 		$10.3K Buy
+12,758
New +$14.7K ﹤0.01% 761

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Pallas Capital Advisors's CHRS Position: Q1 2026 in Review

Pallas Capital Advisors opened a new position in Coherus Oncology (CHRS) in Q1 2026: 11,545 shares worth $19.5K. The stake represents ﹤0.01% of the portfolio and ranks #853 among its holdings. This is a return to the name: Pallas Capital Advisors previously reported a position in CHRS as recently as Q2 2025.

Pallas Capital Advisors first reported a position in CHRS in Q1 2025 and has held it in 3 quarters since. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Pallas Capital Advisors held 11,545 shares of Coherus Oncology worth $19.5K as of Q1 2026.
  • Coherus Oncology was a new Pallas Capital Advisors position in Q1 2026.
  • Coherus Oncology made up ﹤0.01% of Pallas Capital Advisors's portfolio in Q1 2026, its #853 holding.
  • Pallas Capital Advisors first reported a position in Coherus Oncology in Q1 2025 and has held it in 3 quarters since.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Pallas Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.